Medullary Thyroid Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Medullary Thyroid Cancer – Pipeline Review, H2 2016’, provides an overview of the Medullary Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medullary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medullary Thyroid Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Medullary Thyroid Cancer

The report reviews pipeline therapeutics for Medullary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Medullary Thyroid Cancer therapeutics and enlists all their major and minor projects

The report assesses Medullary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Medullary Thyroid Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Medullary Thyroid Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Medullary Thyroid Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Advenchen Laboratories, LLC

Bayer AG

Boehringer Ingelheim GmbH

Celgene Corporation

Hutchison MediPharma Limited

Immunomedics, Inc.

Nerviano Medical Sciences S.r.l.

Novartis AG

Pfizer Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Medullary Thyroid Cancer Overview 8

Therapeutics Development 9

Pipeline Products for Medullary Thyroid Cancer - Overview 9

Pipeline Products for Medullary Thyroid Cancer - Comparative Analysis 10

Medullary Thyroid Cancer - Therapeutics under Development by Companies 11

Medullary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 12

Medullary Thyroid Cancer - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Medullary Thyroid Cancer - Products under Development by Companies 16

Medullary Thyroid Cancer - Products under Investigation by Universities/Institutes 17

Medullary Thyroid Cancer - Companies Involved in Therapeutics Development 18

AbbVie Inc 18

Advenchen Laboratories, LLC 19

Bayer AG 20

Boehringer Ingelheim GmbH 21

Celgene Corporation 22

Hutchison MediPharma Limited 23

Immunomedics, Inc. 24

Nerviano Medical Sciences S.r.l. 25

Novartis AG 26

Pfizer Inc. 27

Medullary Thyroid Cancer - Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Target 29

Assessment by Mechanism of Action 32

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

AL-3818 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

CLM-29 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

CLM-3 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

CLM-94 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

everolimus - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

GI-6207 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

HMPL-012 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

nintedanib - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

NMS-616 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

pasireotide - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

regorafenib - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

rovalpituzumab tesirine - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Small Molecule 1 to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Small Molecule to Inhibit RET Receptor Tyrosine Kinase for Medullary Thyroid Cancer - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

SYN-001 - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

temsirolimus - Drug Profile 92

Product Description 92

Mechanism Of Action 92

R&D Progress 92

TF-2 - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

Medullary Thyroid Cancer - Dormant Projects 96

Medullary Thyroid Cancer - Discontinued Products 97

Medullary Thyroid Cancer - Product Development Milestones 98

Featured News & Press Releases 98

Apr 03, 2013: GlobeImmune Initiates Phase II Study Of New T Cell Stimulating Cancer Vaccine Targeting CEA In Patients With Metastatic Medullary Thyroid Cancer 98

Appendix 99

Methodology 99

Coverage 99

Secondary Research 99

Primary Research 99

Expert Panel Validation 99

Contact Us 99

Disclaimer 100

List of Tables

List of Tables

Number of Products under Development for Medullary Thyroid Cancer, H2 2016 9

Number of Products under Development for Medullary Thyroid Cancer – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Medullary Thyroid Cancer – Pipeline by AbbVie Inc, H2 2016 18

Medullary Thyroid Cancer – Pipeline by Advenchen Laboratories, LLC, H2 2016 19

Medullary Thyroid Cancer – Pipeline by Bayer AG, H2 2016 20

Medullary Thyroid Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 21

Medullary Thyroid Cancer – Pipeline by Celgene Corporation, H2 2016 22

Medullary Thyroid Cancer – Pipeline by Hutchison MediPharma Limited, H2 2016 23

Medullary Thyroid Cancer – Pipeline by Immunomedics, Inc., H2 2016 24

Medullary Thyroid Cancer – Pipeline by Nerviano Medical Sciences S.r.l., H2 2016 25

Medullary Thyroid Cancer – Pipeline by Novartis AG, H2 2016 26

Medullary Thyroid Cancer – Pipeline by Pfizer Inc., H2 2016 27

Assessment by Monotherapy Products, H2 2016 28

Number of Products by Stage and Target, H2 2016 30

Number of Products by Stage and Mechanism of Action, H2 2016 33

Number of Products by Stage and Route of Administration, H2 2016 36

Number of Products by Stage and Molecule Type, H2 2016 38

Medullary Thyroid Cancer – Dormant Projects, H2 2016 96

Medullary Thyroid Cancer – Discontinued Products, H2 2016 97

List of Figures

List of Figures

Number of Products under Development for Medullary Thyroid Cancer, H2 2016 9

Number of Products under Development for Medullary Thyroid Cancer – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 28

Number of Products by Top 10 Targets, H2 2016 29

Number of Products by Stage and Top 10 Targets, H2 2016 29

Number of Products by Top 10 Mechanism of Actions, H2 2016 32

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 32

Number of Products by Routes of Administration, H2 2016 35

Number of Products by Stage and Routes of Administration, H2 2016 35

Number of Products by Molecule Types, H2 2016 37

Number of Products by Stage and Molecule Types, H2 2016 37

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports